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1 Summary 
In the present study, we investigated the acute and chronic effects of amylin and its 
agonist salmon calcitonin (sCT) on energy expenditure in rats. The anorectic effect of 
amylin on food intake is well known. However, the role of amylin in the control of 
energy output is less clear. Based on evidence of an increase in body temperature 
and a body-weight loss after amylin or sCT application, we wanted to test the 
hypothesis that amylin and sCT increase energy expenditure. 
 
Our investigations resulted in the following findings: 
 
o At a dose, that significantly reduced food intake, a single injection of amylin did 
not affect energy expenditure under our conditions. 
 
o SCT, which is more potent than amylin due to sCT’s irreversible binding to the 
amylin receptor, significantly increased energy expenditure when rats had no 
access to food after an acute injection. 
 
o After a chronic infusion of amylin, energy expenditure tended to be increased 
compared to the yoked group, but no effect was observed compared to the saline 
group. 
 
We conclude that amylin may prevent the decrease in energy expenditure that is 
normally seen in animals that eat less. Further, the significant increase in energy 
expenditure after an acute sCT injection suggests that sCT has a stronger effect on 
energy expenditure than amylin,. A chronic infusion of amylin may also prevent the 
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decrease in energy expenditure that would normally occur as a result of reduced food 
intake. 
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2 Introduction 
2.1 Energy balance 
A balance between energy intake and energy expenditure results in a constant body 
weight. These two factors depend on various components like food intake, physical 
activity, basal metabolism, and thermoregulation. Food intake in particular also 
depends on emotions, social factors, habit, time of day and convenience. The latter 
variables are not part of the homeostatic mechanisms that control energy balance, 
but nonetheless affect meal-to-meal energy intake. As a consequence, daily energy 
intake is variable both within and between individuals, and it is not necessarily well 
correlated with energy expenditure on a day to day basis. If energy intake exceeds 
the energy expenditure for a longer period, the excess of energy will be stored as 
body fat which will finally result in obesity. On the other hand, weight-loss can only be 
reached if energy expenditure exceeds energy intake. Despite short-term 
mismatches in energy balance, most people match cumulative energy intake to 
energy expenditure with remarkable precision when measured over a period that 
spans many meals.  
Different hormones play an important role in the long-term control of energy balance. 
The pancreatic hormone insulin, which reaches the brain via the circulation acts in 
the nucleus arcuatus and it reduces energy intake. Insulin was the first hormonal 
signal to be implicated in the control of body weight by the central nervous system 
(CNS) (Woods et al. 1979). The demonstration that the profound hyperphagia and 
obesity of ob/ob mice, resulting from an autosomal recessive mutation of the gene 
encoding for leptin, provided compelling evidence of a second adiposity signal 
(Zhang et al. 1994). Insulin and leptin circulate at levels proportional to body fat and 
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enter the CNS in proportion to their plasma levels (Bagdade et al. 1967; Considine et 
al. 1996; Schwartz et al. 1996). Chronic leptin replacement has been demonstrated 
to cause a marked reduction in food consumption, loss of body weight, elevation of 
body temperature and increase in energy expenditure in ob/ob mice (Campfield et al. 
1995; Halaas et al. 1995; Pelleymounter et al. 1995). Single injection of human leptin 
had a profound effect on whole body energy expenditure in ob/ob mice (Hwa et al. 
1997).  
Recent studies provided evidence that amylin may be a third important hormone 
involved in long term control of energy balance. 
 
2.2 Amylin 
2.2.1 Structure, synthesis and secretion 
Amylin, also known as islet amyloid polypeptide (IAPP), belongs to the family of the 
calcitonin gene peptides. All these peptides, i.e. calcitonin, calcitonin gene related 
peptide (CGRP), amylin and adrenomedullin, have overlapping biological effects 
owing to similar structures and cross-reactivity between receptors (Wimalawansa 
1997). Amylin is a 37-amino acid peptide with a molecular mass of about 3.9 kD 
(Cooper et al. 1987).  It is a normal secretory product of pancreatic ?-cells, which 
constitute amylin’s main production site. Some amylin synthesis also seems to occur 
in the gastrointestinal tract and spinal ganglia (Mulder et al. 1997). 
Amylin is mainly stored in the ?-cell granules of the pancreas (Johnson et al. 1988) 
and it is co-secreted with insulin after glucose or mixed-meal ingestion (Butler et al. 
1990). The release of these two hormones occur at a relatively constant ratio of 
about 1:100 (amylin : insulin) in non-diabetic subjects (Ludvik et al. 1991; Hull et al. 
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2004). Insulin has a short half-life (t1/2 ) of less than 5 minutes compared with amylin . 
Amylin  is cleared through the kidney resulting in a longer t1/2 of about 15 min (Hull et 
al. 2004). Therefore, due to the slower plasma clearance rate of amylin, the ratio of 
amylin and insulin in fasted individuals arises to 1:10.  
 
2.2.2 Regulation of food intake by amylin 
The molar functional unit of eating is a meal. Therefore, eating has to be analyzed in 
terms of the controls of meal initiation (usually called hunger), maintenance of eating 
during the meal (one aspect of food reward), meal termination (satiation), and 
inhibition of eating following meals (postprandial satiety). For most of us, the impetus 
to begin a meal is not based on a biological deficit or need such as insufficient 
glucose or other energy source in some critical tissue. In fact, little is known about the 
physiological controls of meal initiation, maintenance of a meal and postprandial 
satiety. Signals leading to meal termination are comparatively well investigated. One 
of these signals is amylin.  
Early experiments indicated that amylin shares its effect to reduce food intake with 
other peptides of the calcitonin gene peptide family (Chance et al. 1991). A number 
of studies demonstrated amylin’s anorectic effect after peripheral injection. In an early 
study with 12-h food-deprived old (15–18 month) rats, food intake was significantly 
decreased by amylin (1-10 μg/kg) when injected i.p. at the beginning of the dark 
phase. The anorectic effect was most marked in the first 2h after amylin injection and 
was compensated over 24h. In young (7-9 weeks) rats, amylin (0.1-1 μg/kg) dose-
dependently reduced food intake in rats that were food-deprived for 24h (Lutz et al. 
1994). In another study, amylin was injected i.p. at a dose of 1μg/kg at dark onset 
which resulted in a significantly reduced food intake in the first 30 to 60 min after 
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injection (Lutz et al. 1995). The latter study also showed that the anorectic action of 
peripheral exogenous amylin seems to be mainly due to a decrease in meal-size 
especially in the first post-deprivation meal (Lutz et al. 1995; Lutz et al. 2001). 
A conditioned taste aversion test is one possibility to find out if a reduction in food 
intake is due to nausea after administration of a particular substance. Several studies 
have shwon that amylin does not produce a conditioned taste aversion. Neither an 
i.p. injection of amylin nor an intrahypothalamic administration of amylin (1 ?g), which 
is a much higher dose than that used in all other previously described experiments 
with central administration, resulted in a conditioned taste aversion (Chance et al. 
1992a; Lutz et al. 1995; Morley et al. 1997). Studies with amylin antagonists 
confirmed amylin’s specific effect on food intake. It was demonstrated that a 
simultaneous injection of amylin with its antagonists calcitonin gene-related peptide-
(8-37) or AC253 abolished the anorectic effect of amylin (Lutz et al. 1996; Watkins et 
al. 1996). A single peripheral or central injection of the amylin antagonist AC187 
increased food intake presumably by neutralizing the effect of endogenous amylin 
(Mollet et al. 2004; Reidelberger et al. 2004). It therefore can be concluded, that the 
satiating effect of amylin is specific and that endogenous amylin is of physiological 
significance for the control of food intake. 
 
2.2.3 Amylin and area postrema (AP) 
Various studies demonstrated that the area postrema/nucleus of the solitary tract 
(AP/NTS) region plays an important role in the control of food intake. First, it receives 
peripheral satiation signals via splanchnic and vagal afferents from the gastro-
intestinal tract. Second, the AP lacks a functional blood brain barrier, so that blood 
borne signals can directly be monitored in the AP. Furthermore receptors for 
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anorectic peptides such as amylin, CGRP or CCK have been found in this area. 
Finally, thermal ablation of the AP resulted in a significant reduction of the anorectic 
effects of i.p. injected amylin (5 μg/kg), CGRP (5 μg/kg) or sCT (Lutz et al. 1998; Lutz 
et al 2001).  
Immunohistochemical studies for the detection of the expression of the immediate 
early gene product c-Fos protein, a marker of neuronal activation, showed that the 
amylin-induced c-Fos response in AP neurons can be effectively blocked by the 
amylin antagonist AC187. Similar to that of exogenously applied amylin, refeeding, 
i.e. 2h-access to food following a 24h-food deprivation period, also caused 
substantial neuronal activation in the AP and NTS whereas fasted control animals 
showed only minor c-Fos expression. The refeeding-induced c-Fos activation in the 
AP is presumably caused in part by the release of endogenous amylin because the 
blockade of amylin binding sites with AC187 significantly reduced the refeeding 
induced c-Fos expression in AP neurons of rats (Riediger et al. 2004). Peripheral 
amylin administration also activates c-Fos in the lateral parabrachial nucleus (lPBN), 
the bed nucleus of the stria terminalis (BNST) and the central nucleus of the 
amygdala (CeA) (Rowland et al. 1997; Riediger et al. 2004). In AP-lesioned rats, the 
amylin induced c-Fos expression in the NTS, lPBN and CeA was clearly reduced 
(Rowland et al. 1999; Riediger et al. 2004). Therefore it can be concluded that the AP 
is an important primary target area for amylin that is connected to subsequent brain 
regions. 
Electrophysiological in vitro studies showed a direct stimulating effect of amylin on 
AP neurons, underlining their sensitivity to amylin. Amylin dose dependently 
stimulated AP neurons with a threshold concentration in the range of circulating 
plasma amylin concentrations. This finding is consistent with amylin’s anorectic effect 
being dependent on an intact AP. Similar to amylin’s effect on food intake, the in vitro 
 11 
activation of AP neurons by amylin was blocked by AC187 (Riediger et al. 2002; 
Mollet et al. 2004).  
All in all, these findings are consistent with the idea that feeding-induced amylin 
release activates AP neurons which project to subsequent relay stations known to 
transmit meal-related signals to the forebrain. 
 
2.2.4 Amylin’s long term effect on energy balance 
To achieve long-term effectiveness, amylin has to be administered chronically 
because it has a very short half-life of about 15 min in plasma (Hull et al., 2004). A 
single amylin injection results in a significant decrease in food intake only in the first 
hours after administration but a long-term administration of amylin results in a longer 
lasting inhibition of food intake which may also result in an effect on body weight. 
Arnelo et al. (1996) investigated the dose-response effect of peripheral long-term 
administration of amylin on food intake and meal patterns in rats by using s.c. 
osmotic minipumps. Amylin decreased food intake and body weight gain dose 
dependently across the 8-day infusion period. The effect was however transient and 
most marked on the first days of infusion. The analysis of the effects on meal 
patterns demonstrated that the anorexia produced by amylin during the dark and light 
phases occurred through a reduction in the number of meals rather than meal size or 
meal duration (Arnelo et al. 1996). In contrast, Lutz et al. observed that an i.p. 
infusion of amylin mainly resulted in a reduction in meal size, rather than in a 
reduction of the number of meals (Lutz et al. 2001). 
A similar meal pattern effect on the inhibition of food intake was observed after 
central administration. Central infusion of amylin (2.0 pmol/h) via osmotic minipumps 
over 10 days resulted in a significant decrease of food intake. Consequently, by the 
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4th day of infusion, amylin-infused rats weighed significantly less than saline controls. 
This difference persisted throughout the remainder of the infusion period. At sacrifice 
(day 10), the percent of body weight from retroperitoneal fat depots was significantly 
lower in the amylin-treated rats, indicative of a reduction in total body adiposity 
(Rushing et al. 2000). Likewise, Isaksson et al. found a changed lipid metabolism 
after a chronic amylin treatment via subcutaneous osmotic minipumps (25 
pmol/kg/min), which was characterized by decreased adiposity, hypolipidemia and 
hypoleptinemia but unchanged glucose and protein homeostasis (Isaksson et al. 
2005). 
The importance of amylin in the control of energy balance over a prolonged time 
period is also shown in animals with defective leptin or insulin signaling system (e.g. 
ob/ob mice, db/db mice, Zucker fa/fa rats). Even though the animals are able to keep 
their body weight at a fairly constant level, this level is markedly above normal 
(Grabler and Lutz 2004). Food intake and body weight in obese Zucker fa/fa rats, 
e.g., are increased due to a mutation in the leptin receptor gene, leading to inactivity 
of this important long-term control system for food intake and body weight (Schwartz 
2000). Due to the prevailing insulin resistance in these animals, the animals are 
hyperinsulinemic and as a consequence of the co-secretion of insulin and amylin also 
hyperamylinemic. After a chronic infusion with the amylin receptor blocker AC187 
Zucker fa/fa rats showed an increase in food intake. This was not observed in the 
lean control group (Grabler and Lutz 2004). This may indicate that amylin partly takes 
over the role of the long-term controls of food intake leptin and insulin under certain 
conditions, especially when the leptin and insulin signaling systems are deficient. 
Taken together, these findings demonstrate that centrally or peripherally 
administered amylin influences food intake and that amylin may play an important 
role in regulating energy homeostasis.  
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2.3 Salmon calcitonin (sCT) 
The teleost salmon calcitonin (sCT), which has structural similarity to amylin, has 
been shown to act effectively as an anorectic compound via amylin receptors. Such 
evidence for the interaction of sCT with amylin binding sites is the partly blocked 
anorectic action of sCT after CGRP 8-37 or AC187 administration, both antagonists 
of amylin (Lutz et al. 2000). An intracerebral injection of sCT is more potent than 
subcutaneous injection, which also indicates that the anorectic action seems to be 
centrally mediated (Freed et al. 1979). Interestingly, the effect of sCT on food intake 
is more potent than that of mammalian CT in rats (Twery et al. 1982). 
In the subfornical organ, where calcitonin and amylin exert their actions as 
dipsogens, neuronal excitation by sCT was longer lasting than excitation by calcitonin 
and amylin. This is in line with the observation that the anorectic action of sCT is 
prolonged in comparison to that of amylin (Riediger et al. 1999; Riediger et al. 2000; 
Lutz et al. 2000). This may reflect the apparently irreversible binding of sCT to amylin 
and CT binding sites, which has been observed in most in vitro test systems 
(Houssami et al. 1994; Riediger et al. 1999).  
 
2.4 Hormonal influence on energy expenditure 
Energy balance depends on energy intake and energy expenditure. Interestingly, 
besides amylin’s well-known effect on energy intake, some studies provided evidence 
that amylin may also affect the other aspect of energy balance by increasing energy 
expenditure. Therefore, and to understand how body weight is controlled by amylin, 
the knowledge of both aspects of energy balance is important. 
A recent publication showed that after a 3 week infusion of amylin via subcutaneous 
osmotic minipumps, energy expenditure was elevated compared to saline-treated 
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pair-fed and control animals (Roth et al. 2006). Further, Lutz (2006) showed that rats 
which were food deprived for two days, lost more body weight when treated daily with 
sCT than fasted control rats. Because in this experiment rats did not have access to 
food, the data may suggest that sCT stimulates energy expenditure and thereby 
reduces body weight more during fasting than in controls. 
In another study, amylin deficient mice showed an increase in body weight gain 
compared to wild type control mice (Gebre-Medhin et al. 1998; Lutz 2006) 
Interestingly, food intake did not differ between the two groups (unpublished). 
Together, this may  indicate that energy expenditure might have been decreased in 
these knockout mice. 
In general, an effect of amylin on energy expenditure could be due to enhanced 
physical activity, enhanced metabolic rate or raised body temperature. Body 
temperature after an injection of amylin into the paraventricular hypothalamus of rats  
in fact resulted in relative hyperthermia of >1°C (Chance et al. 1992b). In another 
study, a dose dependent hyperthermia was observed with amylin administered into 
the third ventricle at doses of 1.25 to 20 μg. The maximal hyperthermic effect of 
about 1.5°C was reached after 30-60 min. The dose at which hyperthermia was first 
observed was lower for calcitonin gene-related peptide (CGRP) than for rat amylin, 
suggesting that the response may have been mediated via CGRP receptors (Bouali 
et al. 1995). A similar response has also been described for salmon calcitonin 
(Sellami et al. 1993). The doses used in all these experiments, however, are much 
higher than doses used in the studies assessing amylin’s effect on food intake.  
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3 Aim and hypothesis 
The aim of the present study was to investigate the effect of amylin and sCT on 
energy expenditure. Based on the evidence of a body-weight loss and an increase in 
body temperature after an acute or chronic amylin or sCT application, we wanted to 
prove the hypothesis that amylin and sCT increase energy expenditure. First we 
investigated the effect of amylin on energy expenditure after a single injection. The 
next step was to repeat this acute experiment with amylin’s long lasting agonist sCT. 
Thereafter, we investigated the effect of a chronic amylin infusion on energy 
expenditure. Roth et al. (2006) did a similar study with a chronic amylin infusion, 
using pair-fed animals as a control group for amylin-treated rats. In our study we 
used instead the more elaborate paradigm of yoked feeding (see 4.2). This 
procedure allows not only to perfectly match daily food intake but also to exactly 
imitate the meal pattern. 
Because energy expenditure is dependent on various factors like physical activity, 
thermic effect of food (amount and composition) and body temperature, we recorded 
physical activity, body temperature, food and water intake. To observe metabolic 
change, O2 consumption and CO2 production were measured and energy 
expenditure and the respiratory quotient were calculated. 
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4 Animals, material and methods 
4.1 Animals and housing 
All experiments were performed with male Wistar rats (Elevage Janvier, Le Genest–
St-Isle, France) with a body weight of 300 - 350g at the beginning of the study. All 
animals were housed individually in metabolic cages (see 4.3) on a layer of wood 
shavings, in a room with an artificial 12:12-h dark-light cycle (Exp. 1 light on 06.00; 
Exp. 2- 4 light on 03.00; Exp. 5 and 6 light on 21.00). Rats were adapted to the 
housing conditions and to handling for at least 1 week before the start of the 
experiments. All experiments were approved by the Veterinary Office of the Canton 
Zurich, Switzerland. 
 
4.1.1 Diet 
4.1.1.1 Powder chow 
All animals had ad libitum access to water and to standard laboratory rat powder 
chow (3433-9.24 Provimi Kliba, Kaiseraugst), unless otherwise stated (Table 1). 
 
Table 1: Food composition 
(Kliba Mühlen, Art. Nr. 3433-9.24, Kaiseraugst, Schweiz) 
  
Dry substance 
Protein 
Fibre 
Fat 
 
88.0 % 
18.5 % 
4.5  % 
4.5  % 
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Ash 
NFE 
Energy 
Starch 
6.3  % 
54.2  % 
12.5 MJ/kg  
35  % 
 
4.1.1.2 Pelleted chow 
The 45 mg pellets (Grain-Based Rodent Tablet 1811156, TestDiet?, Richmond USA) 
were used for the yoked feeding system in experiments 5 (see 4.8.5) and 6 (see 
4.8.6) (Table 2). 
Table 2: food composition 
(Grain-Based Rodent Tablet 1811156, TestDiet?, Richmond USA) 
  
Dry substance 
Protein 
Fibre 
Fat 
Ash 
NFE 
Energy 
Starch 
 
90.9% 
19.9 % 
4.4  % 
4.7  % 
7.8  % 
54.1  % 
13.8 MJ/kg 
32.8  % 
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4.2 Yoked feeding 
In experiments 5 (see 4.8.5) and 6 (see 4.8.6), we investigated the effect of chronic 
amylin administration on energy expenditure. In these experiments a saline-infused 
yoked fed rat was used as control for each amylin treated rat. The reason for this 
paradigm was, that an amylin injection reduces food intake and this per se results in 
a decrease of energy expenditure. To account for this confounding factor, a saline-
treated rat received a pellet at the same time-point as an amylin-treated rat. This 
procedure allowed not only a perfect match of daily food intake (as in a normal pair-
feeding paradigm) but also to exactly mimic the meal pattern of an amylin-treated rat 
in the corresponding yoked-fed control. Hence, this allowed us to compare the 
energy expenditure between the amylin group and the saline group (=yoked fed 
group), without any confounding influence caused by a difference in total food intake 
or meal pattern. 
Metabolic cages (4.3) were adapted for special food dispensers (Med Associates Inc. 
St.Albans, VT, USA) of 45 mg pellets (see 4.1.1.2). Entry into the food hopper of an 
amylin-treated animal interrupted a light beam. Two consecutive light beam breaks 
triggered the release of a pellet to the food dispenser of the amylin treated rat and 
simultaneously of the saline-infused yoked fed rat. Hence, both animals received a 
pellet at exactly the same time point. Delivered pellets were counted by a computer 
(Software: Med Associates Inc. St.Albans, VT, USA). As a second control group, 
saline-treated rats were used that had ad libitum access to the food hopper. Pellets 
were released whenever the rats crossed the light beam of their own food hopper 
(two light beam breaks/pellet). 
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4.3 Metabolic cages 
An open-circuit indirect calorimetry system was used (Accuscan Instruments, 
Columbus OH, USA). The 12 Plexiglas cages had a size of 42cm x 42cm x 30cm and 
were closed with screws to affirm that the cages were air-tight. 6 cages each were 
connected to one computer, resulting in two independent systems.  
 
4.3.1 Integra System 
The integra System contains the following items for different kinds of recordings. All 6 
cages were measured in alternating order for 20 seconds each so that all data of 
each cage were stored every 2nd minute (experiments 5 and 6 every 3rd minute).  
 
4.3.1.1 Animal Activity System (VersaMax)  
Physical activity was measured via a grid of infrared light beams. 16 x 16 equally 
spaced beams traversed the animal cage from front to back and an equal number of 
beams traversed the same cage from left to right. Vertical sensors monitored rearing 
or jumping activity. The analyzer determined the animal’s position 50 times per 
second and the summary was stored every 2nd minute. Values were recorded in cm.  
 
4.3.1.2 Food and Liquid Consumption System (DietMax) 
Each food or liquid reservoir was placed on a sensitive balance. Differences in 
balance levels were stored and analysed to calculate food intake and water intake. 
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4.3.1.3 Oxygen Consumption/Carbon Dioxide Production System (PhysioScan) 
VO2 (ml/kg/min) and VCO2 (ml/kg/min) were measured every second. Based on these 
measurements energy expenditure and respiratory quotient (RQ = CO2-
production/O2-consumption) were calculated. Ambient air was pumped through the 
cage. The air flow was set to 2 litres per minute. The system recorded the average 
values measured over 20s per cage every 2nd minute in l/min. The system was 
calibrated with a reference tubing measuring O2 in the room of 20.94% and a 12h-
fasted rat with a respiratory quotient of 0.7 before each experiment. 
Energy expenditure was calculated according to Weir (Weir 1949) using the following 
equation:  Total energy expenditure (kcal/h) = (3,9 x ((VO2/1000) x 60)) + (1,1 x 
((VCO2/1000) x 60)). 
 
4.3.1.4 Temperature Telemetry System (VersaMon) 
The temperature system recorded temperatures from small implantable devices 
through radio frequency communications. Before implantation of the temperature 
transmitters they were calibrated by using a jar of water with a defined low and high 
temperature between 33 and 42°C. Each transmitter had a different calibration curve 
(temperature versus frequency). The transmitters were implanted in the abdominal 
cavity with the identity tag in ventral direction (see 4.7.1). 
This system was very difficult to calibrate and no measurements were available if the 
transmitters did not remain in ventral directions, hence whenever the animals moved. 
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4.3.1.5 Dataquest Telemetry System 
Therefore we used a second temperature system in some experiments. The 
PhysioTel? TA-F40 Small Animal Transmitter (Data Science International  Telemetry 
& Dataquest Software, USA) contained sensors for activity and body temperature 
and transmitted this information digitally via telemetry to a receiver, which was placed 
under the cage. Measurements were recorded every 3rd minute. Room temperature 
was also measured. The transmitters incorporated a magnetically activated “on-off” 
switch to conserve battery power. This system was used for experiments 5 (see 
4.8.5) and 6 (see 4.8.6). 
 
4.4 Peptides 
Amylin (Bachem AG; Bubendorf, CH) and salmon calcitonin (Peninsula Laboratories, 
Inc., USA) were diluted in 0,9% NaCl (Fresenius Kabi AG, Stans, Switzerland). The 
concentrations used in the different experiments are indicated in 4.8. 
 
4.5 Intraperitoneal (i.p.) injections 
For the i.p injections, sterile syringes (Omnifix 1 ml, Braun Melsungen AG, 
Melsungen, Germany) and sterile needles (Terumo, 26G, Leuven, Belgium) were 
used. The location of the injection was in the centre of the triangle linea alba – tail 
onset – thigh onset. The volume of injections was 1 ml/kg. 
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4.6 Minipumps 
For the chronic amylin study (see 4.8.5) osmotic minipumps (Alzet?, mini-osmotic 
pump, model 2002, Palo Altro, USA) with a mean pumping rate of 0.5 μl/h were 
implanted (see 4.7.1). The calculated average delivery rate for amylin was 2.0 
μg/kg/h during a 14 day period. For the second chronic experiment (see 4.8.6) a 
pump with a pumping rate of 1 ?l/h (Alzet?, mini-osmotic pump, model 2001, Palo 
Altro, USA) was used. The calculated average delivery rate for amylin was 6 ?g/kg/h 
during an 8 day period. The minipumps were filled with amylin at a concentration of 
1,96 mg/ml for experiment 5 and in a concentration of 2.7 mg/ml for experiment 6. 
The pumps were preincubated in a 0.9% NaCl (Fresenius Kabi AG, Stans, 
Switzerland) at 37°C for 4h, in order to initiate accurate pumping directly after 
implantation. 
 
4.7 Surgical procedure  
4.7.1 Minipumps and temperature transmitters i.p. 
Anaesthesia was induced with 5% isoflurane (IsoFlo?, Provet AG, Lyssach, 
Switzerland) in a small box. The surgery area was shaved and disinfected 
(Betadine?, Provet AG, Lyssach, Switzerland). To prevent corneal desiccation an 
ophthalmic ointment (Vitamin-A Dispersa?, CIBA Vision AG, Niederwangen, 
Switzerland) was placed on both eyes. The rat was transferred to a nose cone and 
the anaesthetic level was reduced to 2-3%.  
After a 1.5 - 2 cm incision in the skin and the linea alba with scissors, the filled sterile 
minipumps or temperature transmitters (VM-FA disc, MiniMitter, Bend OR) were 
placed in the peritoneal cavity. The incision was closed with absorbable suture 
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material (Vicryl 3-0, Ethicon, Norderstedt, FRG) using a continuous suture for the 
linea alba and a single bottom suture for the skin.  
After surgery rats were injected i.m. with chloramphenicol (0.5 ml/kg, Septicol 
Suspension 20%, G.Streuli & Co. AG, Uznach, Switzerland) for antibiotic treatment 
and s.c. with flunixin (0.01 mg/kg; Finadyne?, Provet AG, Lyssach, Switzerland) for 
analgesic treatment. To avoid postsurgery dehydration a 5 ml depot of 0.9%NaCl 
(Fresenius Kabi AG, Stans, Switzerland) was injected s.c. The rats were kept in a 
separate cage with a heat-lamp until they were fully awake. For the following two 
days rats were treated with chloramphenicol p.o. (Chloropal forte?, Dr. E. Gräub AG, 
Bern, Switzerland). 
 
4.7.2 Minipumps subcutaneous 
The same procedure was used for anesthesia as described under 4.7.1. The 
minipumps were placed subcutaneously in the neck after a small incision in the skin. 
The suture was closed using a single bottom suture with absorbable suture material 
(Vicryl 3-0, Ethicon, Norderstedt, FRG). After surgery rats were treated with 
antibiotics and analgesics as describe above. 
 
4.7.3 Intraperitoneal cannulas 
Anaesthesia was induced with 5% isoflurane (IsoFlo?, Provet AG, Lyssach, 
Switzerland) and maintained at 2-3% during surgery. The abdomen and the head 
were shaved and disinfected with Betadine (Betadine?, Provet AG, Lyssach, 
Switzerland). After a rostro-caudal skin incision on the head, the skin was prepared 
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sideward to expose the dorsal skull and to allow placement of 4 screws (0.80 x 1/16; 
Plastics One, Roanoke, VA). 
The abdominal incision went through the skin and the muscles beside the linea alba. 
Thereafter the silicon tubing (O.D. 0.95mm, I.D. 0.5mm; Rubber BV, Hilversum, The 
Netherlands) was drawn under the skin to the rat’s head and connected to an elbow 
(metal part of 20 gauge needles; B.Braun Melsungen AG, Germany) that was fixed 
on the scull with dental cement (Technovit 4071; Powder and Solvent, H. Kulzer & 
Co, GmbH, Wehrheim/Ts., Germany) between the screws. A ring of silicon-glue at 
the abdominal end of the silicon tubing assured a fixation in the abdominal cavity. 
Subsequently the abdominal incision was closed with absorbable suture material 
(Vicryl 3-0, Ethicon, Norderstedt, FRG) using a continuous suture for the muscles 
and a single bottom suture for the skin. Finally the cannula was flushed with 0.9% 
NaCl (Fresenius Kabi AG, Stans, Switzerland).    
 
4.8 Experimental design 
4.8.1 Experiment 1: acute effect of amylin in ad libitum fed rats 
The effect of amylin on energy expenditure was measured using a randomized cross-
over design with at least 2 days between trials. Twenty minutes before dark onset, 
the cages were briefly opened, food was removed and the rats were injected i.p. with 
5 μg/kg amylin or saline as control. The rats were returned to the cages, that were 
closed immediately. Ten minutes later the measurement was started. All parameters 
were measured during the subsequent 24 hours.  
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4.8.2 Experiment 2: acute effect of amylin in food restricted rats 
The access to the food hopper was blocked from 30 minutes before to 3 hours after 
injection. 20 minutes before the middle of the light phase, the cages were briefly 
opened and amylin (1, 5 or 10 μg/kg) or saline as control was injected i.p. The rats 
were returned to the cages, that were closed immediately. 10 minutes later the 
measurement was started in the middle of the light phase. Food access was given 3 
hours after injection. All parameters were measured during 24 hours, i.e. for 3 hours 
during food restriction and for the subsequent 21 hours during ad libitum food 
availability. 
 
4.8.3 Experiment 3: acute effect of amylin administered via i.p. catheter 
in food restricted rats 
One hour before the start of the experiment a clear polyethylene tubing (O.D. 
1.45mm, I.D. 0.5mm; PE 50, Rubber BV, Hilversum, the Netherlands) filled with 
saline was connected from the top of the cage through a small hole in the cage to the 
metal elbow on the head of each animal for the i.p. injections. Thereafter the cages 
were closed and the rats were fasted. 30 minutes later, rats were injected i.p. through 
the cannula with amylin (1, 5 or 10 μg/kg). The tubing was flushed with 0.2 ml saline. 
An air bubble between amylin and saline assured visual control that all amylin was 
injected. Rats were injected in a randomized cross-over design with a minimal 
interval of two days between trials. 
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4.8.4 Experiment 4: acute effect of salmon calcitonin in food restricted 
rats 
In this experiment with a similar design as in experiment 2, energy expenditure was 
measured after an injection with the amylin agonist salmon calcitonin (0.1, 1 or 5 
μg/kg) or saline as control. The trials were separated by at least three days because 
of sCT’s long lasting effect on food intake (Lutz et al. 2000). 
 
4.8.5 Experiment 5: chronic effect of amylin (2 ?g/kg/h i.p.) in rats 
After the implantation of the minipumps and the temperature transmitters (see 4.7.1), 
the measurements were recorded over 10 days. The experiment was performed in 2 
trials using 2 groups of animals because of the capacity of our Accuscan system. 
Every day between 8.00 and 9.00 (light on: 21.00 – 9.00) the systems were stopped, 
data collected and the cages were opened to weigh the rats. Cages were cleaned 
twice per week during the same time window. Food and water were refilled and the 
systems were restarted. Due to amylin’s inhibiting effect on food intake, which 
already results in a decrease in energy expenditure, we used a yoked saline-treated 
animal as a second control for each amylin-treated animal (see 4.2). 
 
4.8.6 Experiment 6: chronic effect of amylin (6 ?g/kg/h s.c.) in rats 
Temperature transmitters were implanted (see 4.7.1) one week before the start of the 
experiment to avoid a body weight loss in the first days caused by the surgery. Just 
before the start of the experiment minipumps were implanted subcutaneously in the 
neck (see 4.7.2). The measurements were recorded over 7 days. The experiment 
was repeated once with a new group of animals. Every day between 8.00 and 9.00 
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the systems were stopped, data collected and the cages were opened to weigh the 
rats and clean the cages. Food and water were refilled and the systems were 
restarted. Due to amylin’s inhibiting effect on food intake, we used a yoked-fed group 
of saline-infused animals as a second control group as in experiment 5 (4.2 and 
4.8.5). 
 
4.9 Statistical analysis 
The data are expressed as mean ± SE. One-way ANOVA with repeated measures 
and post-hoc Bonferroni test for each time point were used to test for significant 
differences, unless otherwise stated. P<0.05 was considered significant. 
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5 Experiments and results 
5.1 Experiment 1: acute effect of amylin in ad libitum fed rats 
In animals with ad libitum access to food, amylin (5 μg/kg) had no effect on energy 
expenditure compared to control when injected just before dark onset (Figure 1). 
Food intake was significantly reduced compared to controls 30 minutes, 1 hour 
(p<0.01) and 2 hours (p<0.05) after injection (Figure 2). Water intake was decreased 
to a similar degree as food intake (Figure 3). RQ (Figure 4), physical activity and 
body temperature (data not shown) were not different from control.  
 
 
Figure 1: Effect of amylin (5 μg/kg i.p.) or saline on energy expenditure. 
Rats (n = 10) were injected in a randomized cross-over design just 
before dark onset. Data are expressed as mean ± SE for every hour.  
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Figure 2: Effect of amylin (5 μg/kg i.p.) or saline on cumulative food 
intake over the first 3h after injection. Rats (n = 10) were injected in a 
randomized cross-over design just before dark onset. Data are 
expressed as mean ± SE. *p<0.05, **p<0.01 (paired t-test).  
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Figure 3: Effect of amylin (5 μg/kg i.p.) or saline on cumulative water 
intake over the first 3h after injection. Rats (n = 10) were injected in a 
randomized cross-over design before dark onset. Data are expressed 
as mean ± SE. *p<0.05, **p<0.01 (paired t-test). 
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Figure 4: Effect of amylin (5 μg/kg i.p.) or saline on respiratory quotient 
(RQ). Rats (n = 10) were injected in a randomized cross-over design 
just before dark onset. Data are expressed as mean ± SE. 
 
5.2 Experiment 2: acute effect of amylin in food restricted rats 
In this experiment, amylin was injected in the middle of the light phase at 3 different 
doses  (1, 5 and 10 μg/kg) in rats without access to food. Energy expenditure was 
slightly but not significantly increased in the first 30 minutes. Overall no effect of 
amylin on energy expenditure was observed (Figure 5). Physical activity, respiratory 
quotient and body temperature (data not shown) were not different from control. After 
refeeding, i.e. 3 hours after injection, no difference in any of the measured 
parameters was observed (data not shown).  
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Figure 5: Effect of amylin (1, 5 or 10 ?g/kg i.p.) on energy expenditure. 
Rats (n = 10) were injected in the middle of the light phase in a 
randomized cross-over design. Data are expressed as mean ± SE. 
 
5.3 Experiment 3: acute effect of amylin administered via i.p. 
catheter in food restricted rats  
One technical problem in the previous experiments was that the airtight metabolic 
cages had to be opened briefly for the administration of amylin. After that, it took 
some time for a stable O2/CO2 measurement to be reached again. It may well be that 
the equilibration of the atmosphere in the metabolic cages after injecting the animals 
might have taken too long for the recording system to detect an effect of amylin on 
energy expenditure. To circumvent this problem cages were closed at least 30min 
before the start of the drug administration in experiment 3 and rats were injected 
through an i.p. canula  (see 4.7.3). An unexpected problem was that rats often bit the 
tubing within the first 3h of recordings. This resulted in a higher physical activity, so 
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that every animal which bit the tubing had to be excluded from the experiment (in 
total four rats). Two rats had to be excluded because the tubing was leaking or 
blocked. 
After acute i.p. amylin infusion in food-restricted rats in the middle of the light phase, 
there was no difference in energy expenditure compared to control rats in any group 
(1, 5 and 10 ?g/kg) (Figure 6). Furthermore no effect on RQ or physical activity was 
found (data not shown). 
 
 
Figure 6: Amylin had no effect on energy expenditure after an acute 
injection of amylin (1, 5 and 10 ?g/kg) via i.p. canulas. Rats (saline n=9; 
amylin 1 ?g/kg n=6; amylin 5 ?g/kg n=7; amylin 10 ?g/kg n=8) were 
injected in a randomized cross-over design in the middle of the light 
phase. Data are expressed as mean ± SE (ANOVA one way). 
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5.4 Experiment 4: acute effect of salmon calcitonin in food 
restricted rats  
Because amylin tended to increase energy expenditure in experiment 2 (see 5.2), the 
next step was to use amylin’s long acting agonist salmon calcitonin, in a similar 
design than in experiment 2. SCT was injected in the middle of the light phase at 3 
different doses (0.1, 1 and 5 ?g/kg) in rats that had no access to food for three hours 
after injection. Energy expenditure was significantly increased 120 min (p<0.01) and 
180 min (p<0.01) after injection of the highest dose of sCT (5 ?g/kg) compared to 
control (Figures 7 and 8). The 1 ?g/kg dose just failed to reach significance compared 
to control at t=120 min (p=0.077) (Figures 7 and 8). RQ was significantly increased 
by 5 ?g/kg sCT at t=120 min (p<0.01) (Figure 9).  
After refeeding energy expenditure was significantly decreased in rats injected with 
sCT compared to control (1 ?g/kg: t=7h p<0.05; normality failed; Dunn’s Method; 5 
?g/kg: t=8h p<0.05 and t=10h p<0.01) (Figure 7). Cumulative food intake was 
significantly reduced at t=6h (p<0.05) and t=8h (p=0.01) in rats injected with 1 ?g/kg 
(Figure 10). With the dose of 5 ?g/kg, food intake was reduced during the entire 
experiment when food was present, i.e. between t=3h and t=24h (t=24h: p<0.05) 
(Figure 10). Food intake was normalized during the wash-out period, indicating that 
there was no carry-over between trials.  
After refeeding RQ was significantly decreased by sCT (5 ?g/kg) from t=4h  (p<0.01) 
to t=16h (p<0.05) (Figure 10). 
Physical activity (Figure 11), body temperature and water intake were not significantly 
different between the groups at any time point during the food restriction from t=0 to 
t=3h (data not shown). 
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Figure 7: Effect of sCT (0.1 ?g/kg, 1 ?g/kg or 5 ?g/kg i.p.) or saline on 
energy expenditure in the first 3 h after injection when rats had no 
access to food. Rats (n = 10) were injected in a randomized cross-over 
design in the middle of the light phase. Data are expressed as mean ± 
SE. **p<0.01, sCT 5 ?g/kg vs. saline (ANOVA one way). 
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Figure 8: Twenty-four hour time course of energy expenditure after 
injection of sCT (0.1 ?g/kg, 1 ?g/kg or 5 ?g/kg i.p.) or saline. Rats (n = 
10) were injected in a randomized cross-over design in the middle of 
the light phase. Data are expressed as mean ± SE. #p<0.05 sCT 1 
?g/kg vs. saline. *p<0.05, **p<0.01 sCT 5 ?g/kg vs. saline (ANOVA one 
way).  
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Figure 9: Twenty-four hour time course of the respiratory quotient after 
injection of sCT (0.1 ?g/kg, 1 ?g/kg or 5 ?g/kg i.p.) or saline. Rats (n = 
10) were injected in a randomized cross-over design in the middle of 
the light phase. Data are expressed as mean ± SE. *p<0.05, **p<0.01 
sCT 5 ?g/kg vs. saline (ANOVA one way).  
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Figure 10: Cumulative food intake after injection of sCT (0.1 ?g/kg, 1 
?g/kg or 5 ?g/kg i.p.) or saline. Rats (n = 10) were injected in a 
randomized cross-over design in the middle of the light phase. Data are 
expressed as mean ± SE. #p<0.05 sCT 1 ?g/kg vs. saline. *p<0.05, 
sCT 5 ?g/kg vs. saline (ANOVA one way).  
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Figure 11: No significant effects were observed on physical activity 
after an acute injection of sCT (0.1, 1 or 5 ?g/kg) in rats (n = 10) in the 
middle of the light phase. Data are expressed as mean ± SE (ANOVA 
one way). 
 
5.5 Experiment 5: chronic effect of amylin (2 ?g/kg/h i.p.) in rats 
In this experiment amylin was infused via i.p. minipumps at a dose of 2 ?g/kg/h over 
10 days. Saline infusion was used as control. The third group of rats was saline 
infused but yoked with the amylin-treated group. 
Amylin slightly reduced food intake on days 1-3 of the infusion. This effect did not 
quite reach significance on any particular day (Figures 13 and 17). Figures 12 – 14 
show the recordings for energy expenditure, cumulative food intake and body 
temperature from day 1 over 23 hours. The drop in energy expenditure and body 
temperature between the light and the dark phase is associated with a circadian 
pattern of lower activity in the light phase. Due to this difference between dark and 
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light phase, daily average recordings are calculated and shown separately for dark 
and light phase. Cumulative food intake on day 1 (Figure 13) was slightly decreased 
in amylin-treated rats. Food-intake in yoked-fed rats corresponded exactly to the 
amount of food in the amylin-treated rats. Rats in all groups ate more during the first 
12 hours (dark phase). In the light phase of day 1, body temperature appeared to be 
slightly lower in the yoked fed group compared to the amylin or saline control (Figure 
14). For the following days only 12-h dark phase average values and light phase 
average values (11 h) are shown for most parameters. 
The strong reduction of energy expenditure in the dark phase in all groups on day 1 
was most likely caused by the surgery on day 0 (Figure 15). Although the effect of 
amylin on energy expenditure was not significant, it seems that for the following days 
amylin clearly prevented the decrease in energy expenditure compared to the yoked 
group in the light phase as well as in the dark phase (Figures 15 and 16). Lower 
energy expenditure in the yoked fed rats compared to the saline ad libitum fed rats 
was expected because the reduced food intake in the yoked fed rats physiologically 
results in a decrease in energy expenditure. In general, energy expenditure in the 
dark phase was higher compared to the light phase, most likely in part due to higher 
physical activity in the dark phase. The observed effect of amylin on energy 
expenditure compared to yoked rats was slightly stronger in the light phase than in 
the dark phase (Figures 15 and 16). 
No change in body weight was observed in the saline group after surgery on day 0. 
These rats started to gain body weight after day 5. Amylin-treated rats significantly 
lost body weight from day 1 to 4 compared to the saline group. The difference to the 
yoked group was only seen on day 1. The amylin group slightly gained body weight 
after day 3 but tended to have a lower body weight during the entire experiment than 
the saline group and reached levels of the yoked group after day 5. The yoked-fed 
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rats did not loose body weight after surgery on day 0. The biggest body weight loss in 
the yoked-fed group occurred between days 1 and 2. On the following days they 
slightly gained body weight (Figure 18). 
The effect of amylin on body temperature was stronger in the light phase than in the 
dark phase. Body temperature in the light phase was significantly increased on days 
1, 3 and 5 in the amylin group compared to the yoked-fed rats (Figure 20). No effect 
was observed on physical activity (Figures 21 and 22) and RQ (data not shown). 
 
 
Figure 12: Effect of amylin (2 ?g/kg/h i.p.) or saline infusion on energy 
expenditure on day 1 in rats (n = 8). Data are expressed as mean ± SE 
for every hour (ANOVA one way).  
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Figure 13: Effect of amylin (2 ?g/kg/h i.p.) or saline infusion on 
cumulative food intake on day 1 in rats (n = 8). Yoked fed rats were 
infused with saline but their food intake was yoked to that of amylin 
infused rats. Data are expressed as mean ± SE for every hour (ANOVA 
one way).  
 
 
 43 
 
Figure 14: Effect of amylin (2 ?g/kg/h i.p.) or saline infusion on body 
temperature on day 1 in rats (n = 8). Data are expressed as mean ± SE 
for every hour (ANOVA one way).  
 
 
Figure 15: Average dark phase energy expenditure during chronic 
infusion of amylin (2 ?g/kg/h) or saline in rats (n = 8). Data are 
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expressed as mean ± SE for  the dark phase of every day (ANOVA one 
way).  
 
 
Figure 16: Average light phase energy expenditure during chronic 
infusion of amylin (2 ?g/kg/h) or saline in rats (n = 8). Data are 
expressed as mean ± SE for every day (ANOVA one way).  
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Figure 17: Effect of a chronic amylin infusion (2 ?g/kg/h i.p.) on daily 
food intake in rats (n = 8). Yoked fed rats were infused with saline but 
their food intake was yoked to that of amylin infused rats. Data of 
average daily food intake are expressed as mean ± SE (ANOVA one 
way). 
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Figure 18: Effect of chronic amylin infusion on body weight change in 
rats (n = 8). Amylin treated rats lost significantly more body weight on 
days 1-4 compared to saline. The difference between amylin and yoked 
rats was significant on day 1. Data are expressed as mean ± SE for 
every day.  a: p<0.05 amylin vs. saline; b: p<0.05 amylin vs. yoked 
(ANOVA one way). 
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Figure 19: Average dark phase body temperature during chronic 
infusion of amylin (2 ?g/kg/h) or saline in rats (n = 8). Data are 
expressed as mean ± SE for every day (ANOVA one way). 
 
 
Figure 20: Average light phase body temperature during chronic 
infusion of amylin (2 ?g/kg/h) or saline in rats (n = 8). Data are 
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expressed as mean ± SE for every day. c: p<0.05 amylin vs. yoked 
(ANOVA one way). 
 
 
Figure 21: Average dark phase physical activity during chronic infusion 
of amylin (2 ?g/kg/h) or saline in rats (n = 8). Data are expressed as 
mean ± SE for every day (ANOVA one way).  
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Figure 22: Average light phase physical activity during chronic infusion 
of amylin (2 ?g/kg/h) or saline in rats (n = 8). Data are expressed as 
mean ± SE for every day (ANOVA one way).  
 
5.6 Experiment 6: chronic effect of amylin (6 ?g/kg/h s.c.) in rats 
In the second chronic experiment, the dose of amylin was increased to 6 ?g/kg/h. 
Amylin was infused s.c. and data were recorded for 7 days. Energy expenditure was 
significantly reduced in amylin treated rats and the yoked rats on day 1 in the light 
and in the dark phase (Figures 23 and 24). This decrease is probably caused by the 
strong amylin-induced reduction of food intake on day 1 (see Figure 25). Amylin 
treated rats were not different from the saline group on day 2 although food intake 
was still significantly reduced. Further, yoked fed animals had a significantly reduced 
energy expenditure on days 6 and 7 in the dark phase, while amylin treated rats were 
not different from control. These effects indicate that amylin clearly prevented a 
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decrease of energy expenditure when associated with the amount of food eaten 
(Figures 23 and 24). 
Food intake in amylin treated animals and in the yoked rats was significantly reduced 
on days 1 and 2 and regained control levels on the following days (Figure 25).  
Saline treated rats did not loose body weight after implantation of the minipumps. The 
amylin treated group lost body weight on day 1 compared to the saline group. Body 
weight of amylin treated rats after day 3 was slightly lower for the rest of the 
treatment period compared to the saline group. Yoked fed rats lost significantly more 
body weight on days 1 and 2 and they had a significantly lower body weight 
compared to saline control during the entire experiment (Figure 26). 
Body temperature of amylin treated rats was not different from the saline group.  
Yoked fed rats had a significantly lower body temperature compared to the saline 
group on days 4, 5 and 7 in the dark phase and on days 1, 3, 6 and 7 in the light 
phase. During the entire treatment period yoked fed animals had a lower body 
temperature than amylin treated rats (Figures 27 and 28).  
No effect was observed on physical activity (Figures 29 and 30) and RQ (data not 
shown). 
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Figure 23: Average dark phase energy expenditure during chronic 
infusion of amylin (6 ?g/kg/h) or saline in rats (n = 8). Data are 
expressed as mean ± SE for every day. a: p<0.05 amylin vs. saline, b: 
p<0.05 yoked vs. saline, c: p<0.05 amylin vs. yoked (ANOVA one way). 
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Figure 24: Average light phase energy expenditure during chronic 
infusion of amylin (6 ?g/kg/h) or saline in rats (n = 8). Data are 
expressed as mean ± SE for every day. a: p<0.05 amylin vs. saline; b: 
p<0.05 yoked vs. saline (ANOVA one way). 
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Figure 25: Effect of a chronic amylin infusion (6 ?g/kg/h s.c.) on daily 
average food intake in rats (n = 8). Data are expressed as mean ± SE 
for every day. a: p<0.05 amylin vs. saline; b: p<0.05 yoked vs. saline 
(ANOVA one way). 
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Figure 26: Effect of a chronic amylin (6 ?g/kg/h s.c.) or saline infusion 
on body weight change in rats (n = 8). Data are expressed as mean ± 
SE for every day. a: p<0.05 amylin vs. saline; b: p<0.05 yoked vs. 
saline (ANOVA one way). 
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Figure 27: Average dark phase body temperature during chronic 
infusion of amylin (6 ?g/kg/h) or saline in rats (n = 8). Data are 
expressed as mean ± SE for every day. b: p<0.05 yoked vs. saline 
(ANOVA one way). 
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Figure 28: Average light phase body temperature during chronic 
infusion of amylin (6 ?g/kg/h) or saline in rats (n = 8). Data are 
expressed as mean ± SE for every day. b: p<0.05 yoked vs. saline 
(ANOVA one way). 
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Figure 29: Average dark phase physical activity during chronic infusion 
of amylin (6 ?g/kg/h) or saline in rats (n = 8). Data are expressed as 
mean ± SE for every day (ANOVA one way). 
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Figure 30: Average light phase physical activity during chronic infusion 
of amylin (6 ?g/kg/h) or saline in rats (n = 8). Data are expressed as 
mean ± SE for every day (ANOVA one way). 
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6 Discussion 
6.1 Summary of the results 
A balance between energy intake and energy expenditure results in a constant body 
weight. The effect of amylin on food intake has been well investigated. However 
amylin’s role in the control of energy output is not well established. The aim of the 
present study was therefore to investigate the acute and chronic effects of amylin and 
its agonist sCT on energy expenditure in rats. At a dose which significantly reduced 
food intake, a single injection of amylin did not significantly affect energy expenditure 
when injected in rats either at dark onset with ad libitum access to food, or when 
injected in the middle of the light phase without access to food. On the other hand, 
sCT, which has a more potent and long lasting effect on food intake due to its 
irreversible binding to the amylin receptor, significantly increased energy expenditure 
when rats had no access to food after a single injection. Refeeding resulted in a 
significant decrease of energy expenditure after an acute injection of sCT. This may 
have been due to the very strong reduction in feeding that was obvious at that time. 
After a chronic infusion of amylin, energy expenditure tended to be increased 
compared to the yoked group but no effect was observed compared to the saline 
group. Body temperature was elevated in amylin infused rats, and they lost more 
body weight compared to the saline group. There was no effect on physical activity. 
Food intake was only reduced during the first days of chronic amylin treatment.  
 
6.2 Effect of an acute amylin injection 
A single injection of amylin (5 ?g/kg) at dark onset had no effect on energy 
expenditure while food and water intake were significantly reduced 1h and 2h after 
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amylin administration. This reduction in food intake and water intake is consistent 
with previous studies (Lutz et al. 1994; Lutz et al. 1995b). Usually a reduction in food 
intake results in a decrease in energy expenditure (Passadore et al. 2004). Therefore 
our findings may indicate that amylin prevented the compensatory decrease in 
energy expenditure associated with a reduced food intake. This was also recently 
suggested by Mack et al. (2006) and Roth et al. (2006).  
To exclude the possible confounding factor of amylin’s effect on food intake, which 
might per se affect energy expenditure, rats were without access to food for 3h after 
the injection in the next experiment. Because rats are less active and hardly consume 
any food in the light phase, we performed the experiment in the middle of the light 
cycle. This was presumed to cause less stress as if rats had been fasted during their 
active night phase. Fasting during the light phase decreased this potential stress 
factor as much as possible (Del Prete et al. 1993).  
The experiment was set up with three different doses of amylin (1, 5 and 10 ?g/kg). 
Like in the first experiment amylin had no clear effect on energy expenditure. There 
was only a slight non-significant increase 30min after injection. It is possible that the 
short half-life of amylin (? 13min [Young 2005] prevented a possible acute effect of 
amylin on energy expenditure after a single injection at a near-physiological dose. 
Because the air-tight cages had to be opened briefly just before the administration of 
amylin and because it took some time for a stable O2/CO2 measurement to be 
reached again it may well be that the equilibration of the atmosphere in the metabolic 
cages after injecting the animals might have taken too long for the recording system 
to detect a significant effect of amylin. 
To circumvent the latter problem, rats were injected through a pre-implanted i.p. 
canula (see 4.8.3) in the next experiment. However, again no effect on energy 
expenditure was observed within the 3h after injection.  
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Because in some experiments the reported ED50 of amylin for food intake in rats is 
?25 ?g/kg, which is more than two times higher than the highest dose in our study, it 
cannot be excluded that the dose of amylin used in our experiments was too low to 
have a significant effect on energy expenditure (Young 2005). 
 
6.3 Effect of an acute salmon calcitonin injection 
Therefore, and because amylin at least tended to increase energy expenditure in 
food-restricted rats, we performed the next experiment with amylin’s agonist salmon 
calcitonin. In fact a single injection of sCT (5 ?g/kg) in the middle of the light phase in 
fasted rats resulted in a significant increase in energy expenditure. A possible 
explanation for the difference to the previous experiment with amylin is that sCT’s 
effect is much longer lasting than amylin’s effect due to an irreversible binding to the 
amylin receptor (Beaumont et al. 1993; Muff et al. 1995; Lutz et al. 2000). In parallel 
to the increase in energy expenditure, RQ was significantly elevated for the first 3h 
after the injection of the highest dose of sCT (5 ?g/kg). This effect could be the result 
of some metabolic change, like a shift from fat oxidation to carbohydrate or protein 
oxidation. During fat oxidation RQ is about 0.7, during protein oxidation RQ is about 
0.8 and during carbohydrate oxidation RQ is about 1.0. Usually RQ is the result of a 
mixed oxidation. Our results are not consistent with a study by Roth et al. They 
observed a decrease in RQ in amylin treated and pair-fed rats relative to vehicle 
controls, consistent with the decreased caloric intake in the former groups (Roth et al. 
2006). The reason for the discrepant results is unclear. 
After refeeding a significant decrease in energy expenditure and RQ were observed 
at the highest dose of sCT and, at least at some timepoints, also with the lower dose 
of 1 ?g/kg sCT. These effects are probably caused by the strong reduction in food 
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intake, which may have overruled the direct effect on energy expenditure by sCT. 
During this period, the values of the RQ were close to 0.7, indicating a high lipid 
oxidation which is typical for animals that eat very little. 
Similar to the previous experiments, no significant effect of sCT was observed on 
physical activity, suggesting that the increase in energy expenditure is caused by 
another mechanism. Roth et al. also observed that changes in spontaneous physical 
activity were not associated to the changes in energy expenditure (Roth et al. 2006). 
Other studies showed that doses of amylin that decrease food intake do not induce 
competing locomotor activities (i.e. hypo- or hyperactivity) (Roan et al. 2005). Upon 
central administration, high dose of amylin have been shown to decrease locomotor 
activity, an effect that would more likely be consistent with a reduction, rather than an 
enhancement, in energy expenditure (Clementi et al. 1996). 
 
6.4 Effect of a chronic amylin infusion  
Because amylin tended to increase energy expenditure after a single injection, and 
because sCT significantly increased energy expenditure after an acute injection, two 
additional experiments were performed with a chronic amylin infusion. In the 
experiment with the lower dose of amylin (2 ?g/kg/h), energy expenditure was not 
significantly affected compared to the saline control group. However the yoked rats 
showed lower energy expenditure over the entire experimental period. This may 
suggest that there is in fact an effect of amylin on energy expenditure, because food 
intake was identical in the latter two groups and there was no effect on physical 
activity. Therefore, like in the acute studies, it seems that amylin prevented a 
decrease in energy expenditure that would typically be seen in animals that eat or 
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weigh less. The lower level of energy expenditure in pair-fed rats is consistent with a 
study of Roth et al. (2006). 
Another indication that is consistent with this interpretation for an amylin induced 
effect on energy balance was observed in a study with amylin knockout-mice. These 
mice gained significantly more body weight compared to wildtype mice although 
cumulative food intake was not different, suggesting that energy expenditure was 
decreased in amylin knockout-mice (Gebre-Medhin et al. 1998; Lutz 2006). 
In our study and despite the similar food intake in amylin-treated and yoked-fed rats, 
body weight loss was higher in the first days of amylin infusion. This is in line with 
Roth et al. They examined the body composition after a chronic amylin infusion (i.e, 
300 ?g/d) over 22 days, hence with a dose which is a two- or sixfold higher dose than 
what we used in our experiments. In Roth’s study there was no difference in body 
weight change between amylin-treated rats and their pair-fed controls. Use of rats 
yoked to the amylin group is clearly advantageous to normal pair-feeding. Pair-fed 
rats receive the same amount of food, that was eaten by amylin treated rats on the 
day before. Yoked rats in our experiments received the same amount of food at the 
same timepoint as the control group. Therefore, because the amount of food that 
pair-fed rats receive is lower than the amount of food that they would eat under ad 
libitum feeding conditions, this “restricted” feeding may result in a fasting period at the 
end of the day. This is avoided with the yoked design. Roth et al. reported that 
carcass lipids tended to be reduced by simple caloric restriction, but only amylin-
treated rats had a significantly lower percentage of fat and a significantly higher 
percentage of carcass protein, compared with the vehicle group. Body composition of 
pair-fed rats did not differ from that of vehicle-treated rats. Nuclear magnetic 
resonance analysis of body fat content before and after treatment showed that amylin 
and pair-feeding significantly reduced body fat relative to vehicle-treated rats. 
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However, amylin-treated rats lost significantly more fat than their pair-fed controls. 
Whereas amylin tended to slow the rate of gain of lean mass relative to vehicle 
controls, pair-feeding significantly reduced lean body mass. To examine whether 
there was regionally specific fat loss, selected fat depots were dissected and 
weighed. Amylin, but not pair feeding, significantly reduced retroperitoneal fat 
compared with vehicle controls (Roth et al. 2006). A specific decrease in epididymal 
fat pads after a chronic infusion was also observed in a study of Isaksson et al. 
These results confirm an effect of amylin on body composition although the 
mechanism is not completely investigated. 
In our study amylin infusion resulted in an increased body temperature, especially in 
the light phase. This may explain the lack of decrease in energy expenditure, despite 
lower food intake. An effect of amylin on body temperature was also observed in a 
study by Bouali et al. They showed a dose-dependent increase in body temperature 
after acute central injections of amylin into the third ventricle (Bouali et al. 1995).  The 
same effect was seen after a central injection into the PVN (Chance et al. 1992b). It 
should be noted, however, that these effects were seen after injections with much 
higher doses than we used in our studies. Although the mechanisms underlying the 
effect on body temperature under all these experimental conditions remains to be 
clarified, the presence of amylin immunoreactivity in the hypothalamus lends support 
to a possible role for amylin in thermoregulatory mechanisms (Chance et al. 1992b). 
It has been shown that amylin increases the concentration of serotonin in the 
hypothalamus (Chance et al. 1991; Chance et al. 1992b). Thus, it is possible that the 
hyperthermia induced by amylin is modulated via the release of serotonin because 
i.c.v. administration of serotonin is known to increase body temperature in animals 
(Blatteis 1981). Interestingly, however, amylin’s anorectic effect is independent of the 
serotoninergic system. 
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The lower levels in energy expenditure, physical activity and food intake on day 1 
compared to the following days are probably the result of the surgery on day 0. The 
main effects on body weight change, food intake and body temperature were mainly 
seen in the first days of the treatment, indicating that amylin was less effective after 
some days. Roth et al. also observed the main effects of amylin during the first week 
of their treatment period of 3 weeks. Similar to our studies they observed a strong 
decrease in food intake on days 1 to 4 and a body weight loss until day 3. On the 
following days body weight was stabilized (Roth et al. 2006). The strong reduction of 
food intake in the first days of a chronic amylin infusion is consistent with other 
studies (Arnelo et al. 1996; Isaksson et al. 2005).  
Due to these promising effects of a low dose chronic amylin infusion the last 
experiment was performed with a higher dose of amylin (6 ?g/kg/h). To avoid the 
strong effect of surgery on body weight seen in the previous experiment, temperature 
transmitters were already implanted a week before the start of the experiment and 
minipumps were implanted subcutaneously on day 0. In this experiment we observed 
a strong decrease of energy expenditure on the first day in the amylin and yoked 
groups. This was probably caused by a strong reduction in food intake, which 
overruled the direct effect on energy expenditure. On the following days, energy 
expenditure of the yoked fed rats was lower compared to the amylin group, although 
food intake was exactly the same. The reason for this is most probably the lower 
body temperature in yoked rats, because there was no difference in physical activity 
between groups. Body weight decrease on the first two days of this experiment was 
significantly stronger in amylin and yoked rats compared to the saline group. On the 
following days, however, yoked fed rats lost more body weight than amylin treated 
rats. This is in contrast to the first experiment using a lower dose of amylin and with 
the study of Roth et al. (Roth et al. 2006). Because there was no difference in 
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physical activity, food intake and water intake and body temperature was decreased, 
we do not have an explanation for this. If the yoked group were more stressed, due to 
restricted food availability, this would rather be expected to result in an increase in 
energy expenditure.  
Overall we conclude that the experiment with the higher dose of amylin (6 ?g/kg/h) 
was only more effective on food intake compared to the previous one (2 ?g/kg/h). In 
both chronic experiments, the effect of amylin was relatively short-lasting, indicating 
that amylin was less effective after some days. Several mechanisms for amylin-
induced desensitization have been proposed, including downregulation of the 
receptor or substrate consumption at the second messenger level (Furnsinn et al. 
1993). Huang et al. observed a desensitization of amylin receptors in rat pancreatic 
acinar AR42J cells when they were pretreated with amylin but not with sCT or CGRP 
(Huang 1995). However, Roth et al. as well as Arnelo et al., observed a longer lasting 
effect of amylin with the same or higher amylin doses (Arnelo et al. 1996; Roth et al. 
2006). 
 
6.5 Final conclusions 
In summary, a single bolus injection of a (near) physiological dose of amylin did not 
significantly influence energy expenditure when given at dark onset in rats that had 
ad libitum access to food or when given in the middle of the light phase to rats 
without access to food. However, the data indicate that amylin may prevent the 
decrease in energy expenditure that is normally seen in animals that eat less. Further 
an acute injection of sCT resulted in a significant increase in energy expenditure 
compared to controls when rats did not have access to food. This suggests that sCT 
had a stronger effect on energy expenditure than amylin itself, most likely due to its 
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irreversible binding to the amylin receptor. A chronic amylin infusion did not 
significantly influence energy expenditure compared to yoked rats and controls. 
Nevertheless, like in the acute studies, it seems that amylin tended to prevent a 
decrease in energy expenditure that would normally occur as a result of reduced food 
intake. This study shows that amylin may not only affect energy balance through its 
inhibitory effect on food intake, but also by influencing energy expenditure. 
 
6.6 Future research 
Several studies seem imperative to extend the knowledge on amylin’s effect on 
energy expenditure. Because we only tested exogenous amylin it would be important 
to perform an experiment with amylin’s antagonist AC187 which should block the 
action of endogenous amylin. Administration of this antagonist is expected to result in 
a decrease in energy expenditure.  
Further we plan to perform an experiment with amylin knockout-mice. Because they 
gained more body weight compared to wildtype mice although food intake was 
similar, it would be expected that energy expenditure was reduced in the knockout-
mice. Further we expect that the effect can be rescued when replacing amylin. 
To avoid amylin desensitization in a chronic setup as possibly observed here, amylin 
could be infused intermittently e.g. only in the dark phase or only in the light phase. 
This could be performed with minipumps connected to a tubing, alternately filled with 
amylin and a control solution.  
Finally, a study with central amylin infusions may probably affect energy expenditure 
stronger than an i.p. injection because an effect on food intake after central 
administration also occurs at lower doses than when given peripherally. 
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